← Eichor
Study identifier: NCT03608280 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficiency of 3D-printed Implant Versus Autograft for Orbital Reconstruction (TOR-3D)

Condition: Significant Bone Defect in the Orbit  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants92
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

Two scenarios may result in significant bone defect in the orbit: surgical oncology (meningioma, cancers of the upper aerodigestive tract) or severe trauma. This defect in the bone substance may affect the orbital floor, medial wall or lateral wall. These injuries can result in functional complications such as enophthalmos and diplopia, and an esthetic impact affecting the quality of life. The most frequent complication in orbital traumas is enophthalmos (10-20% according to publications). The aim of bone substance reconstruction is to restore the volume and the internal shape of the orbit. The gold standard is autologous bone grafts. The surgery which usually lasts 2 to 3 hours depending on the number of walls involved, can lead to ophthalmological or esthetic complications. Its results are unsatisfactory, and the use of titanium implants would allow a reconstruction of the orbital volume more optimal than the autograft. The development of computer-assisted techniques permitted implants evolution: initially peri-operatively preformed, today patient specific implant can be obtained from data of CT-scan. In cranioplasties, a randomized study showed better results at 12 months of these implants compared to the autograft. Their success rate is close to 100% with less than 5% of postoperative complication, while the rate used for cortical graft reconstructions is 20-25%. Today, 3D printing of patient-specific porous titanium implants is possible. A study has shown that they al…

This description comes directly from the study's public registry record.

Talk to the study team

Jean-Thomas BACHELET  ·  +33 4 26 73 26 44  ·  jean-thomas.bachelet@chu-lyon.fr

Magali HANSER  ·  +33 4 72 11 57 65  ·  magali.hanser@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hospices Civils de Lyon, Groupement Hospitalier Sud Chirurgie maxillo-facialePierre-Bénite, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03608280